Exact Therapeutics AS (OL:EXTX) — Stock Price
Exact Therapeutics AS (OL:EXTX) is currently trading at Nkr0.75 NOK, up 0.00% today. Over the past 52 weeks, shares have ranged between Nkr0.65 and Nkr2.92. This page tracks Exact Therapeutics AS's live share price on the OL exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Exact Therapeutics AS market capitalisation.
Exact Therapeutics AS (EXTX) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Exact Therapeutics AS's daily closing share price and trading volume on the OL exchange over the past year, giving a clear view of recent price momentum and liquidity.
Exact Therapeutics AS Income Statement — Revenue, Profit & Earnings by Year
Exact Therapeutics AS's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | Nkr0.00 | Nkr0.00 | Nkr0.00 | Nkr0.00 | Nkr0.00 |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Research & Development | Nkr25.21 Million | Nkr19.74 Million | Nkr19.91 Million | Nkr34.49 Million | Nkr13.31 Million |
| SG&A | Nkr23.13 Million | Nkr22.31 Million | Nkr5.39 Million | Nkr5.50 Million | Nkr18.05 Million |
| Total Operating Expenses | Nkr52.85 Million | Nkr48.38 Million | Nkr40.77 Million | Nkr59.11 Million | Nkr34.70 Million |
| Operating Income | Nkr-52.85 Million | Nkr-48.38 Million | Nkr-40.77 Million | Nkr-59.11 Million | Nkr-34.70 Million |
| EBITDA | — | — | Nkr-38.46 Million | Nkr-56.66 Million | Nkr-31.98 Million |
| EBIT | — | — | Nkr-40.77 Million | Nkr-59.11 Million | Nkr-34.70 Million |
| Interest Expense | Nkr54.46K | Nkr85.64K | Nkr98.93K | Nkr100.11K | Nkr23.62K |
| Income Before Tax | Nkr-52.33 Million | Nkr-48.38 Million | Nkr-40.57 Million | Nkr-58.59 Million | Nkr-33.09 Million |
| Income Tax Expense | — | — | Nkr-462.08K | — | — |
| Net Income | Nkr-52.33 Million | Nkr-48.33 Million | Nkr-40.10 Million | Nkr-58.59 Million | Nkr-33.09 Million |
Exact Therapeutics AS Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Exact Therapeutics AS's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | Nkr153.20 Million | Nkr61.32 Million | Nkr82.51 Million | Nkr117.63 Million | Nkr170.23 Million |
| Total Current Assets | Nkr133.21 Million | Nkr55.90 Million | Nkr77.53 Million | Nkr111.30 Million | Nkr165.71 Million |
| Cash & Equivalents | Nkr99.54 Million | Nkr46.43 Million | Nkr69.39 Million | Nkr82.91 Million | Nkr138.92 Million |
| Short-term Investments | — | — | Nkr0.00 | Nkr20.78 Million | Nkr20.50 Million |
| Net Receivables | — | — | Nkr8.14 Million | Nkr7.61 Million | Nkr5.99 Million |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | Nkr4.81 Million | Nkr5.42 Million | Nkr4.97 Million | Nkr6.33 Million | Nkr4.52 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | Nkr37.65 Million | Nkr16.22 Million | Nkr17.40 Million | Nkr11.89 Million | Nkr10.58 Million |
| Total Current Liabilities | Nkr37.60 Million | Nkr15.49 Million | Nkr16.13 Million | Nkr10.53 Million | Nkr10.58 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | Nkr115.55 Million | Nkr45.10 Million | Nkr65.11 Million | Nkr105.74 Million | Nkr159.65 Million |
| Retained Earnings | — | Nkr0.00 | Nkr-40.14 Million | Nkr-122.01 Million | Nkr-63.45 Million |
Exact Therapeutics AS Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Exact Therapeutics AS generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | Nkr-80.55 Million | Nkr-44.30 Million | Nkr-33.85 Million | Nkr-55.11 Million | Nkr-25.99 Million |
| Capital Expenditures | Nkr1.51 Million | Nkr3.09 Million | Nkr250.98K | Nkr1.63 Million | Nkr3.96 Million |
| Free Cash Flow | Nkr-82.05 Million | Nkr-47.39 Million | Nkr-34.10 Million | Nkr-56.74 Million | Nkr-29.95 Million |
| Investing Cash Flow | Nkr-580.74K | Nkr-2.15 Million | Nkr20.60 Million | Nkr-1.01 Million | Nkr-980.87K |
| Financing Cash Flow | Nkr134.33 Million | Nkr23.17 Million | Nkr-530.69K | Nkr-47.39K | Nkr142.57 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | Nkr2.82 Million | Nkr3.96 Million | Nkr-398.42K | Nkr4.16 Million | Nkr7.85 Million |
| Depreciation | Nkr2.43 Million | Nkr2.09 Million | Nkr1.94 Million | Nkr1.83 Million | Nkr902.65K |
| Change in Cash | Nkr53.11 Million | Nkr-22.96 Million | Nkr-13.52 Million | Nkr-56.31 Million | Nkr115.47 Million |
Exact Therapeutics AS Earnings History — EPS Actual vs. Analyst Estimates
Track Exact Therapeutics AS's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Sep 10, 2025 | — | — | — |
| Apr 09, 2025 | — | — | — |